(Q37334965)

English

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

scientific article published on September 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

1 reference

based on heuristic

inferred from title

cytokine release syndrome

1 reference

based on heuristic

inferred from title

Stefania Pittaluga

14

object named as

Stefania Pittaluga

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Wyndham H. Wilson

13

object named as

Wyndham H Wilson

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Georg Aue

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ndegwa Njuguna

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Xin Tian

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Susan Soto

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Thomas Hughes

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Berengere Vire

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Keyvan Keyvanfar

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Federica Gibellini

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Janet Valdez

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Carol Boss

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Leigh Samsel

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

J Philip McCoy

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Adrian Wiestner

15

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

1 September 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

94

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1266-1273

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

Lenalidomide for the treatment of B-cell malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

Immunomodulating drugs for chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

6 September 2017

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

14 September 2017

Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

28 September 2017

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

2 September 2018

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

2 September 2018

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738719

2 September 2018

CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/19734418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transmembrane signaling through CD80 (B7-1) induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19734418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/19734418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides

1 reference

https://pubmed.ncbi.nlm.nih.gov/19734418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19734418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2009.005835

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37334965&oldid=2208745759"